ANALYSIS OF THE FREQUENCY AND FEATURES OF THE CLINICAL COURSE OF AUTOIMMUNE THYROIDITIS IN COMBINATION WITH CELIAC DISEASE
DOI:
https://doi.org/10.21856/j-PEP.2025.2.04Keywords:
autoimmune thyroiditis, celiac disease, autoimmune pathology of the small intestine, polyglandular syndrome, gluten intolerance without celiac disease, hypothyroidismAbstract
The aim of the study was to determine the frequency and features of the clinical course of autoimmune thyroiditis (AIT) in combination with autoimmune pathology of the small intestine (coeliac disease, gluten intolerance without celiac disease).
Materials and methods. 173 patients (three age groups: I – 5-20, II – 21-45, III – 46-60 years) with an antithyroid peroxidase (anti-TPO) antibody level in the blood over 600 μIU/mL were examined: n=35 men/138 women. Thyroid status was assessed by the levels of thyroid-stimulating hormone (TSH), free thyroxine (fT4) and free triiodothyronine (fT3). Ultrasound diagnostics was also used to visualize the thyroid gland (TH). To verify celiac disease, anti-tissue transglutaminase IgA antibody (anti-tTG IgA) (U/mL), anti-tissue transglutaminase IgG antibody (anti-tTG IgG) (U/mL), anti-gliadin (deaminated peptides) IgA antibody (anti-G IgA) (U/mL), anti-gliadin IgG antibody (anti-G IgG) (U/mL) and serum immunoglobulin A (IgA) levels (g/L) were determined using the immunoturbidimetric method on the “ELIA Phadia” analyzer. Statistical processing of the results was performed using the Package for Social Sciences v.19.0 (SPSS Inc., Chicago, Il, USA).
Results and conclusions. It was found that 32.4% of patients with AIT of all age groups have a high titer of anti-tTG and/or anti-G. During screening examination in the group of patients with AIT under 20 years of age, a positive titer of anti-tTG IgG was detected in 14.3%, anti-G IgG in 17.9%, in the group of patients aged 21-45 years - in 10.5 and 27.6%, respectively; in the group of patients aged 46-60 years - in 5.8 and 23.2%, respectively. Simultaneously positive titer of IgG and IgA anti-tTG and anti-G is observed in 2.3% of patients, which, in the presence of pronounced activity of antithyroid immunity, moderate hypothyroidism, erased gastrointestinal symptoms and other nonspecific extraintestinal clinical signs, allows establishing the diagnosis of "Celiac disease" with a high degree of probability. In other cases, if only an elevated titer of anti-G IgG is present, “Gluten intolerance without celiac disease” is diagnosed. Given the low frequency (2.89%) of high titers of anti-tTG and anti-G IgA, their use as diagnostic criteria in screening patients with AIT is not advisable. In the presence of combined polyglandular autoimmune endocrine pathology in combination with other autoimmune non-endocrine diseases, it is necessary to diagnose celiac disease using anti-tTG and anti-G of both IgA and IgG classes. The established linear positive strong correlation (r= 0.83, p=0.01) between the levels of anti-G IgG and anti-TPO proves that with high titers of anti-TPO in patients with AIT, the severity of the immune response to the pathological effect of gluten increases.
References
1. Singh P, Arora A, Strand TA, et al. Clin Gastroenterol Hepatol 2018;16(6): 823-836. https://doi.org/10.1016/j.cgh.2017.06.037
2. Lebwohl B, Sanders DS, Green PH. Lancet 2018;391(10115): 70-81. https://doi.org/10.1016/S0140-6736(17)31796-8
3. Dyrka K, Obara-Moszyńska M, Niedziela M. Endokrynol Pol 2024;75(5): 461-472. https://doi.org/10.5603/ep.100701
4. Escudero-Hernández C. Elsevier 2021: 133-164. https://doi.org/10.1016/bs.ircmb.2020.09.007
5. Iversen R, Sollid LM. Annu Rev Pathol 2023;18: 47-70. https://doi.org/10.1146/annurev-pathmechdis-031521-032634
6. Lebwohl B, Rubio-Tapia A. Gastroenterology 2021;160(1): 63-75. https://doi.org/10.1053/j.gastro.2020.06.098
7. Sharma BR, Joshi AS, Varthakavi P, et al. Indian J Endocrinol Metab 2016;20(1): 97-100. https://doi.org/10.4103/2230-8210.172241
8. Cooper BT, Holmes GK, Cooke WT. Br Med J 1978;1(6112): 537-539. https://doi.org/10.1136/bmj.1.6112.537
9. Midhagen G, Järnerot G, Kraaz W. Scand J Gastroenterol 1988;23(8): 1000-1004. https://doi.org/10.3109/00365528809090160
10. Caturegli P, De Remigis A, Rose NR. Autoimmun Rev 2014;13(4-5): 391-397. https://doi.org/10.1016/j.autrev.2014.01.007
11. Thyroid disease: assessment and management. NICE guideline [NG145], available at: https://www.nice.org.uk/guidance/ng145
12. Al-Toma A, Volta U, Auricchio R, et al. United European Gastroenterol J 2019;7(5): 583-613. https://doi.org/10.1177/2050640619844125
13. Brunn J, Block U, Ruf G, et al. Dtsch Med Wschr 1981;106(41): 1338-1340. https://doi.org/10.1055/s-2008-1070506
14. Lakyn GF. Byometryja: ucheb. posobye dlja byol. spec. vuzov. 4-e yzd., Мoskva, 1990: 352 p.
15. Minelli R, Gaiani F, Kayali S, et al. Acta Biomed 2018;89(9): 11-16. https://doi.org/10.23750/abm.v89i9-S.7872
16. Elfström P, Montgomery SM, Kämpe O, et al. J Clin Endocrinol Metab 2008;93: 3915-3921. https://doi.org/10.1210/jc.2008-0798
17. Kalyouncu D, Urganci N. Int J Endocrinol 2015: 276575. https://doi.org/10.1155/2015/276575
18. Roy A, Laszkowska M, Sundström J, et al. Thyroid 2016;26: 880-890. https://doi.org/10.1089/thy.2016.0108
19. Pham-Short A, Donaghue KC, Ambler G, et al. Pediatrics 2015;136: e170-e176. https://doi.org/10.1542/peds.2014-2883
20. Albatineh A, Dehvan F, Shariari H. Clin Diabetol 2021;10: 447-461. https://doi.org/10.5603/DK.2021.0055
21. Elfstrom P, Sundstrom J, Ludvigsson JF. Aliment Pharmacol Ther 2014;40: 1123-1132. https://doi.org/10.1111/apt.12973
22. Tsouka A, Mahmud FH, Marcon MA. J Pediatr Gastroenterol Nutr 2015;61(3): 297-302. https://doi.org/10.1097/MPG.0000000000000789
23. Ludvigsson JF, Rubio-Tapia A, van Dyke CT, et al. Am J Gastroenterol 2013;108(5): 818-824. https://doi.org/10.1038/ajg.2013.60
24. Makharia GK, Chauhan A, Singh P, Ahuja V. Aliment Pharmacol Ther 2022;56(1): S3-S17. https://doi.org/10.1111/apt.16787
25. Besser HA, Khosla C. Trends Pharmacol Sci 2023;44(12): 949-962. https://doi.org/10.1016/j.tips.2023.09.006
26. Godfrey JD, Brantner TL, Brinjikji W, et al. Gastroenterology 2010;139(3): 763-769. https://doi.org/10.1053/j.gastro.2010.05.041
27. Cook HB, Burt MJ, Collett JA, et al. J Gastroenterol Hepatol 2000;15(9): 1032-1036. https://doi.org/10.1046/j.1440-1746.2000.02290.x
28. Lohi S, Mustalahti K, Kaukinen K, et al. Aliment Pharmacol Ther 2007;26(9): 1217-1225. https://doi.org/10.1111/j.1365-2036.2007.03502.x
29. Mustalahti K, Catassi C, Reunanen A, et al. Ann Med 2010;42(8): 587-595. https://doi.org/10.3109/07853890.2010.505931
30. Gnodi E, Meneveri R, Barisani D. World J Gastroenterol 2022;28(4): 449-463. https://doi.org/10.3748/wjg.v28.i4.449
31. Catassi C, Verdu EF, Bai JC, Lionetti E. Lancet 2022;399(10344): 2413-2426. https://doi.org/10.1016/S0140-6736(22)00794-2
32. Nistico L, Fagnani C, Coto I, et al. Gut 2006;55(6): 803-808. https://doi.org/10.1136/gut.2005.083964
33. Kuja-Halkola R, Lebwohl B, Halfvarson J, et al. Gut 2016;65(11): 1793-1798. https://doi.org/10.1136/gutjnl-2016-311713
34. Khosla C. ACS Chem Biol 2017;12(6): 1455-1459. https://doi.org/10.1021/acschembio.6b01155
35. Toscano V, Conti FG, Anastasi E, et al. Am J Gastroenterol 2000;95(7): 1742-1748. https://doi.org/10.1111/j.1572-0241.2000.02187.x
36. Guariso G, Conte S, Presotto F, et al. Aliment Pharmacol Ther 2007;26(10): 1409-1417. https://doi.org/10.1111/j.1365-2036.2007.03526.x
37. Husby S, Koletzko S, Korponay-Szabo I, et al. J Pediatr Gastroenterol Nutr 2012;54(1): 136-160. https://doi.org/10.1097/MPG.0b013e31821a23d0
38. Schuppan D, Pickert G, Ashfaq-Khan M, Zevallos V. Best Pract Res Clin Gastroenterol 2015;29(3): 469-476. https://doi.org/10.1016/j.bpg.2015.04.002
39. Hyzhnjak O, Nikolajev R, Mans'ka K, et al. Probl Endokryn Patol 2023;80(1): 73-81. https://doi.org/10.21856/j-PEP.2023.1.09
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Problems of Endocrine Pathology

This work is licensed under a Creative Commons Attribution 4.0 International License.
ISSN
ISSN 






